Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

116 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Rationale for treatment and study design of tailor: a randomized phase III trial of second-line erlotinib versus docetaxel in the treatment of patients affected by advanced non-small-cell lung cancer with the absence of epidermal growth factor receptor mutations.
Farina G, Longo F, Martelli O, Pavese I, Mancuso A, Moscetti L, Labianca R, Bertolini A, Cortesi E, Farris A, Fagnani D, Locatelli MC, Valmadre G, Ardizzoia A, Tomirotti M, Rulli E, Garassino MC, Scanni A. Farina G, et al. Among authors: moscetti l. Clin Lung Cancer. 2011 Mar;12(2):138-41. doi: 10.1016/j.cllc.2011.03.008. Epub 2011 Apr 11. Clin Lung Cancer. 2011. PMID: 21550561 Clinical Trial.
Management of PALB2-associated breast cancer: A literature review and case report.
Toss A, Ponzoni O, Riccò B, Piombino C, Moscetti L, Combi F, Palma E, Papi S, Tenedini E, Tazzioli G, Dominici M, Cortesi L. Toss A, et al. Among authors: moscetti l. Clin Case Rep. 2023 Aug 22;11(8):e7747. doi: 10.1002/ccr3.7747. eCollection 2023 Aug. Clin Case Rep. 2023. PMID: 37621724 Free PMC article.
Predictive factors for relapse in triple-negative breast cancer patients without pathological complete response after neoadjuvant chemotherapy.
Toss A, Venturelli M, Civallero M, Piombino C, Domati F, Ficarra G, Combi F, Cabitza E, Caggia F, Barbieri E, Barbolini M, Moscetti L, Omarini C, Piacentini F, Tazzioli G, Dominici M, Cortesi L. Toss A, et al. Among authors: moscetti l. Front Oncol. 2022 Dec 1;12:1016295. doi: 10.3389/fonc.2022.1016295. eCollection 2022. Front Oncol. 2022. PMID: 36531080 Free PMC article.
Gemcitabine with or without continuous infusion 5-FU in advanced pancreatic cancer: a randomised phase II trial of the Italian oncology group for clinical research (GOIRC).
Di Costanzo F, Carlini P, Doni L, Massidda B, Mattioli R, Iop A, Barletta E, Moscetti L, Recchia F, Tralongo P, Gasperoni S. Di Costanzo F, et al. Among authors: moscetti l. Br J Cancer. 2005 Jul 25;93(2):185-9. doi: 10.1038/sj.bjc.6602640. Br J Cancer. 2005. PMID: 15986036 Free PMC article. Clinical Trial.
Induction therapy with paclitaxel and carboplatin followed by hyperfractionated radiotherapy plus weekly concurrent chemotherapy and subsequent consolidation therapy in unresectable locally advanced non-small-cell lung cancer.
Cortesi E, Moscetti L, Nelli F, De Marinis F, De Paula U, Bangrazi C, Migliorino MR, Donato V. Cortesi E, et al. Among authors: moscetti l. Tumori. 2007 Mar-Apr;93(2):133-7. doi: 10.1177/030089160709300204. Tumori. 2007. PMID: 17557558 Clinical Trial.
116 results